12 results about "Human pancreas" patented technology

The invention relates to the technical field of biological medicine, and discloses an aromatic polyketone compound as well as a preparation method and application thereof. According to the aromatic polyketone compound, a compound I and a compound II are separated from an ethyl acetate extract of rice fermentation liquor of Crystalomyces hyricus, and the compound I and the compound II are respectively named as Crystaloketide A and Crystalomycin D. In-vitro anti-cancer activity tests are carried out on the Crystaloketide A and the Crystalomycin D. According to the aromatic polyketone compound disclosed by the invention, the anti-cancer activity of the Crystaloketide A and the Crystalomycin D. Results show that the compound I and the compound II have the effects of inhibiting human cervical cancer cells, human liver cancer cells, human nerve cancer cells and human pancreatic cancer cells respectively, so that the compound I and the compound II can be further prompted to be used for preparing anti-cancer drugs.

This invention relates to the field of biomedical technology, and discloses an aromatic polyketide compound, its preparation method, and its applications. The aromatic polyketide compound is derived from... Crystallomyces hypericus Compound I and Compound II were isolated from the ethyl acetate extract of rice fermentation broth and identified as Crystalloketide A and Crystallomycin D, respectively. In vitro anticancer activity tests were conducted on Crystalloketide A and Crystallomycin D. The results showed that Compound I and Compound II inhibited human cervical cancer cells, human liver cancer cells, human neurocancer cells, and human pancreatic cancer cells, respectively. Therefore, it is further suggested that Compound I and Compound II described in this invention can be used to prepare anticancer drugs.

The invention belongs to the technical field of biological medicine, and particularly discloses a tetravalent platinum rhein conjugate and application of the tetravalent platinum rhein conjugate in preparation of anti-cancer drugs, and the tetravalent platinum rhein conjugate has a structure as shown in a formula I or a formula II. Pharmacodynamic experiments show that compared with existing platinum drugs, rheinic acid, combined drugs of the platinum drugs and the rheinic acid and structural analogues, the tetravalent platinum rheinic acid conjugate disclosed by the invention shows unexpected ultra-strong inhibitory activity in order of magnitude on various solid tumor cells, especially on human pancreatic cancer cells MIAPaca-2. Animal in-vivo experiments further prove that the compound has an excellent tumor inhibition effect and good safety. The invention provides a candidate compound with great potential for developing a new generation of high-efficiency and low-toxicity anti-cancer drug, especially an anti-pancreatic cancer drug.

This invention discloses an acidic polysaccharide from Gynostemma pentaphyllum, AGPA12, its purification and extraction method, and its application in the preparation of anti-pancreatic cancer drugs. AGPA12 is mainly composed of mannose, glucuronic acid, rhamnose, glucose, galactose, and fucose, with a molar ratio of 1.05:1.74:6.29:1.40:69.48:19.03. The polysaccharide was extracted using an α-amylase-assisted water extraction and alcohol precipitation method, and purified by DEAE-Sepharose FF ion exchange chromatography and Sepharose CL6B gel chromatography. In vitro experiments showed that AGPA12 had significant inhibitory effects on the proliferation and migration of human pancreatic cancer AsPC1 cells, and its mechanism was related to the regulation of the MAPK signaling pathway and the expression of apoptosis-related proteins. This invention provides a new approach for the development of Gynostemma pentaphyllum polysaccharides and their application in anti-pancreatic cancer drugs.

The application discloses an anti-tumor small-molecule compound targeting ST3GAL1 and application thereof, and the small-molecule compound is N'-[1-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-4-methoxybenzohydrazide, and the structure is shown in the following formula I: The application obtains an anti-tumor small-molecule compound targeting ST3GAL1 through virtual screening, the small-molecule compound can inhibit the expression of ST3GAL1, and has the potential to be applied to tumor treatment and preparation of anti-tumor drugs; experiments show that the small-molecule compound has significant inhibitory effects on human pancreatic cancer PANC-1 cell lines and human in situ pancreatic cancer BxPC-3 cell lines after 48 hours of action, and the inhibitory effects are in a dose-dependent manner, wherein the IC50 value of the small-molecule compound on the PANC-1 cells is 42.17 micromoles, and the IC50 value of the small-molecule compound on the BxPC-3 cells is 46.83 micromoles.

The invention discloses an oleanolic acid acylhydrazone derivative as well as a preparation method and application thereof. The oleanolic acid acylhydrazone derivatives have a structural formula shown in the following formula I. In the structural formula, R is selected from halogen-substituted pyridine and hydroxyl-substituted naphthyl. The invention provides a series of oleanolic acid acylhydrazone derivatives with novel structures, and the oleanolic acid acylhydrazone derivatives have relatively good inhibition effects on human breast cancer cells MDA-MB-231 and human pancreatic cancer cells Mia paca-2, and can be used for preparing an anti-cancer drug. The compound can be used for preparing anti-tumor drugs.

The application discloses a 1,3,4-oxadiazole derivative containing a biphenyl unit and a preparation method and application thereof, a structural formula of the derivative is shown as formula I, and the preparation method is that an oxadiazole molecule containing a phenoxy (sulfone) methyl is subjected to a substitution reaction with 2-bromo-4'-phenyl phenylethanone in a solvent containing potassium carbonate to obtain a target compound. The 1,3,4-oxadiazole derivative containing the biphenyl unit has obvious inhibiting effects on human pancreatic cancer cells (PANC-1) and human hepatoma cells (HepG2), and can be used as a potential new type of antitumor candidate drug molecule.

This application relates to the pharmaceutical field, and particularly to SOS1 protein degraders and their applications. The compounds of this application can effectively inhibit tumor cell proliferation and degrade SOS1 protein in tumor cells, with a maximum degradation rate of 96.15%. Compared with existing small molecule compounds, the compounds of this application exhibit a more sustained inhibitory effect on SOS1 signaling and a more significant inhibitory effect on the growth of human MIA PaCa-2 pancreatic cancer subcutaneous xenografts in mice, with a maximum tumor volume inhibition rate (TGI) of 81.3%.

This invention relates to a novel *Bletilla striata* alkaloid boric acid compound, its preparation method, and its use in the preparation of antitumor drugs. The general chemical formula of this class of compounds is shown in structural formulas (I) and (II). In vitro antitumor activity screening results showed that compounds of formulas I and II possess broad-spectrum antitumor activity, exhibiting strong inhibitory activity against human liver cancer (HepG2), human pancreatic cancer (SW1990), human ovarian cancer (A2780), human breast cancer (MCF7), and human colon cancer (SW480) cell lines. Compounds N-3 and N-4 showed strong inhibitory effects against all five tested tumor cell lines, with IC50 values ​​exceeding 100%. 50 The values ​​were 0.26–0.89 μM and 0.22–0.91 μM, respectively; compounds N-1, N-3, and N-4 exhibited strong inhibitory effects on the human pancreatic cancer (SW1990) cell line, with IC50 values ​​of 0.26–0.89 μM and 0.22–0.91 μM, respectively. 50 The concentrations were 0.97, 0.45, and 0.63 μM, respectively, significantly superior to the control drug topotecan; simultaneously, compounds N-3 and N-4 also exhibited strong inhibitory effects on the human breast cancer (MCF7) cell line, with IC50 values ​​of 0.97, 0.45, and 0.63 μM. 50 The concentrations were 0.80 and 0.65 μM, respectively, significantly better than the control drug topotecan. Therefore, the new cypermethrin borate compound holds promise for development into a novel antitumor drug.

Provided herein are materials and methods relating to the fields of immunology and diabetes. More specifically, provided herein are methods and compositions directed to humanized antibodies to human zinc transporter-8 (ZnT8), a biomarker of human pancreatic beta-cells.

The invention discloses a human pancreatic cancer cell line PDAC-X6 and application thereof, and belongs to the field of microbial animal cell lines. The human pancreatic cancer cell line is named as a human pancreatic cancer cell line PDAC-X6 homo sapiens, and is preserved in the China Center for Type Culture Collection on November 22, 2025, and the preservation number is CCTCC NO: C2025355. The human pancreatic cancer cell line PDAC-X6 can be applied to establishment of a cell model for occurrence, development or metastasis of pancreatic cancer. The human pancreatic cancer cell line PDAC-X6 can be applied to cell models for studying the differentiation mechanism, cell morphology and dysfunction and tumor infiltration and metastasis mechanism of pancreatic cancer and guiding clinical comprehensive diagnosis and treatment. The human pancreatic cancer cell line PDAC-X6 can be applied to research on the occurrence mechanism of pancreatic cancer and screening of drugs for preventing and treating pancreatic cancer. The human pancreatic cancer cell line PDAC-X6 can be applied to establishment of a pancreatic cancer animal model.

The application discloses a novel coumarin derivative containing a quinazoline unit (as shown in structural formula I), and a preparation method thereof. The preparation method comprises the following steps: subjecting a coumarin molecule A treated by a sodium hydroxide solution to etherification reaction with a 4-chloroquinazoline molecule B in acetonitrile by heating, and then subjecting an intermediate product C obtained by the reaction to reaction with benzyl chloride or bromoethane in acetonitrile by heating, so as to obtain the novel coumarin derivative I containing the quinazoline unit. The novel coumarin derivative containing the quinazoline unit is a novel compound, has obvious inhibiting effect on human pancreatic cancer cells (PANC-1), human gastric cancer cells (SGC7901) and human breast cancer cells (MDA-MB-231), and can be developed as a novel anti-tumor drug candidate molecule.